Oncogenic <i>KRAS</i>-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities
Pancreatic ductal adenocarcinoma (PDAC) remains highly refractory to treatment. While the <i>KRAS</i> oncogene is present in almost all PDAC cases and accounts for many of the malignant feats of PDAC, targeting KRAS or its canonical, direct effector cascades remains unsuccessful in patie...
Guardado en:
Autores principales: | Sapana Bansod, Paarth B. Dodhiawala, Kian-Huat Lim |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5d817c7138c64e199ef506aadd7b6506 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeting Tumor-Stromal Interactions in Pancreatic Cancer: Impact of Collagens and Mechanical Traits
por: Parniyan Maneshi, et al.
Publicado: (2021) -
Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer
por: Lu T, et al.
Publicado: (2021) -
The role of tumoral stroma in determining the forecast of recurrence and fatal consequence of stage IIA-IIIB colorectal cancer
por: Alina Yakimenko
Publicado: (2021) -
CT Radiomics and Machine-Learning Models for Predicting Tumor-Stroma Ratio in Patients With Pancreatic Ductal Adenocarcinoma
por: Yinghao Meng, et al.
Publicado: (2021) -
Impact of Tumor–Stroma Ratio on the Prognosis of Colorectal Cancer: A Systematic Review
por: Jinlai Gao, et al.
Publicado: (2021)